Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients.

van der Sijde, Fleur; Vietsch, Eveline E; Mustafa, Dana A M; Besselink, Marc G; Groot Koerkamp, Bas; van Eijck, Casper H J

van der Sijde, Fleur; Vietsch, Eveline E; Mustafa, Dana A M; Besselink, Marc G; Groot Koerkamp, Bas; van Eijck, Casper H J.

Afiliação

van der Sijde F; Department of Surgery, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. f.vandersijde@erasmusmc.nl.
Vietsch EE; Department of Surgery, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. e.vietsch@erasmusmc.nl.
Mustafa DAM; Department of Pathology, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. d.mustafa@erasmusmc.nl.
Besselink MG; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. m.g.besselink@amc.uva.nl.
Groot Koerkamp B; Department of Surgery, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. b.grootkoerkamp@erasmusmc.nl.
van Eijck CHJ; Department of Surgery, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. c.vaneijck@erasmusmc.nl.

Cancers (Basel) ; 11(1)2019 Jan 15.

Article em En | MEDLINE | ID: mdl-30650521

Palavras-chave

FOLFIRINOX; chemotherapy response; gemcitabine; pancreatic cancer; predictive circulating biomarker

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google